What Commercial Due Diligence Questions Should PE Firms Ask About GTM Effectiveness?

Private equity firms must probe beyond surface-level pipeline numbers to assess the underlying go-to-market engine. Key questions should target Ideal Customer Profile (ICP) clarity, pipeline quality versus quantity, new logo acquisition rates, empirical (not anecdotal) sales team competence, and the true cost of customer acquisition, revealing hidden growth constraints, post-close risks and illuminating an integration roadmap.

TL;DR

• Go beyond the bridge slide. Most go-to-market (GTM) diligence barely scratches the surface, validating headline numbers without testing the integrity of the underlying revenue engine. QoE is a backward looking snapshot. In contrast, QoS (Quality of Sales) is predictive.
• The pipeline is often a fantasy. Ask for defined pipeline stages with quantitative AND QUALITATIVE exit criteria, win rates from qualified stages, and deal velocity. Learn what % of opportunities are DISqualified from each stage. A large pipeline full of unqualified opportunities is a liability, not an asset.
• Assess the team, not just the leader. Question the hiring process. Does it select for "industry experience" (a lagging indicator) or for the business acumen needed to sell outcomes? A team built to maintain accounts cannot drive new logo acquisition.
• Process separates scalable businesses from lifestyle businesses. Look for a documented sales process that is coached and enforced, a consistent sales methodology, and playbooks. Without them, you are acquiring a collection of individual reps, not a scalable revenue system.
• The real risk is the timeline. A broken GTM engine can consume 18 to 24 months of a five-to-seven year hold period just to fix foundational issues, putting the entire value creation plan in jeopardy. Diligence is your first, best chance to scope the problem.

The GTM Diligence Gap: Why Most PE Firms Get It Wrong

In a typical due diligence process, the rigor applied to finance and operations is exhaustive. We model scenarios, scrutinize the balance sheet, and walk the factory floor to identify inefficiencies. Then we get to the go-to-market function, and that discipline often evaporates.

We look at the CRM pipeline report, listen to the sales leader’s forecast, and check the box. The assumption is that sales is more art than science, a function driven by relationships and gut feel.

This is a profound and costly mistake.

A manufacturing company would never tolerate a 40% defect rate on its production line. Yet, we routinely accept that 40 to 60% of sales reps will chronically miss quota. We accept forecasts that are consistently wrong. We accept that 70% of revenue comes from the same group of existing customers, a clear sign of an inability to win new logos.

These aren't just quirks of the sales profession. They are symptoms of a broken system. Effective commercial due diligence isn't about validating the numbers on a bridge slide. It's about stress-testing the system that produces those numbers, understanding the gaps, adjusting valuation, and building an integration plan to solve for them simultaneously while working on finance and operations.

Beyond the Obvious: The Questions That Reveal the Truth

To understand the real health of a target company’s GTM engine, you need to ask a different set of questions. These questions peel back the veneer of a healthy pipeline to expose the structural cracks beneath.

Question 1: How Real is the Pipeline?

The most common mistake is confusing pipeline size with pipeline quality. A bloated pipeline is often a sign of a weak or nonexistent qualification process, which is why 40 to 60% of deals in many industrial companies end in "no decision."

The conventional diligence question is: "What’s the total value of your pipeline?"

The right questions are:

• What are your documented pipeline stages, and what are the specific, buyer-verified exit criteria for each? If they can't produce this, there is no consistent process for qualifying opportunities. These should include qualitative criteria to substantiate quantitative.
• What is your win rate on deals that reach the proposal or quote stage? This separates real opportunities from the "quote-and-pray" activities that keep reps busy but don't produce revenue. But close rate is meaningless if we don't solve for consistency in the denominator with rigorous opportunity qualification.
• What is the average deal velocity? How long does it take for an opportunity to move from discovery to close? A slow or unpredictable velocity points to a lack of control over the sales process.
• What % of opportunities result in NO decision? Deals that are neither won nor lost, but simply clog the pipeline and eventually age off are indicative of weak salesmanship.
• What percentage of the pipeline is generated by marketing versus sales? This reveals whether the company has a demand generation engine or is entirely reliant on the prospecting heroics of individual reps.

Question 2: Can the Sales Team Actually Sell, or Do They Just Take Orders?

The second major failure is evaluating sales talent on the wrong criteria. Most industrial companies hire for industry experience and a good rolodex. They evaluate them on their total revenue. Both are terrible predictors of success in driving new business.

This practice produces reps who are comfortable talking about product specs with plant engineers but lack the business acumen to hold a value-based conversation with a CFO or CEO. They are experts at "finding projects" that are already in motion, a game where data shows the winner is likely already chosen 70% of the time. They are incapable of "creating projects" by engaging executives early to shape the buying vision around a business outcome.

The conventional diligence question is: "Tell me about your top reps."

The right questions are:

• What is your hiring methodology for sales talent? Are you screening for specific competencies like business acumen, financial literacy, and the ability to manage a complex, multi-stakeholder sale? Or are you just recycling the same industry veterans? Specialist programs like Sales Talent Hiring & Recruiting from firms like Ed Marsh Consulting build a repeatable process for finding people who can execute a modern growth playbook.
• Show me the quota attainment distribution for the last eight quarters. Is it a healthy bell curve, or are two stars carrying the entire team while the rest fail? The latter is a massive key-person risk.
• What unique behaviors to top performers have? Or do they have a particular territory, concentration risk, or were they handed house accounts?
• What percentage of last year's revenue came from new logos? If it’s under 30%, you are likely acquiring an account management team, not a new business acquisition engine. This is a critical red flag if your value creation plan depends on organic growth.

Question 3: Is There a Repeatable Process or Just Individual Heroics?

Scalable growth comes from a system, not from a handful of talented individuals doing their own thing. Without a defined process and methodology, you cannot train, coach, or scale the sales function. When a top rep leaves, their performance leaves with them.

This is another area where the disparity between operational and commercial discipline is stark. No PE-backed manufacturer would run its shop floor without standardized work instructions, but they allow their revenue engine to operate on tribal knowledge and ad-hoc tactics.

The conventional diligence question is: "What’s your sales strategy?"

The right questions are:

• Can you show me your documented sales process map? Opportunity qualification scorecard?
• What sales methodology (e.g., MEDDICC, Challenger, etc.) does the team use to prosecute and qualify deals? If the answer is "we don't have one" or "everyone has their own style," there is no scalable system.
• Are there sales playbooks for key buyer personas, industries, or competitive scenarios?
• Is there a formal pre-call planning process and template? A lack of planning discipline is a leading indicator of low-quality sales calls.

The Real Risk is Post-Close Stagnation

Failing to ask these questions during diligence doesn't just mean you might overpay. The far greater risk is the impact on your hold period.

When a portfolio company’s GTM engine is fundamentally broken, the first 18 to 24 months of the value creation plan are consumed by triage. You spend two years realizing it's not working and then the next two years fixing the hiring process, defining and implementing a sales process, training a team that was never built for proactive growth, and potentially replacing a sales leader who was hired based on the same flawed "industry experience" criteria. Four years of a five-year hold can be vaporized before you even begin to execute the growth plan you modeled. This is the cycle of stalled value creation we see constantly in the middle-market industrial space.

Commercial due diligence, therefore, isn't simply a risk mitigation exercise. It's the first and most critical step in creating value. It's about building a clear, evidence-based picture of the revenue engine so you can accurately scope the work required post-close. It's about knowing whether you're acquiring a finely tuned machine or a fixer-upper that will require a complete teardown and rebuild. Your investment thesis depends on knowing the difference.

That's the power of the Quality of Sales approach.

Frequently Asked Questions